English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Cervarix (human papillomavirus1 type 16 L1 protein...) – Conditions or restrictions regarding supply and use - J07BM02

Updated on site: 05-Oct-2017

Medication nameCervarix
ATC CodeJ07BM02
Substancehuman papillomavirus1 type 16 L1 protein / human papillomavirus type 18 L1 protein
ManufacturerGlaxoSmithKline Biologicals S.A.

A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers of the biological active substance

GlaxoSmithKline Biologicals SA Parc de la Noire Epine

rue Flemming 20-1300 Wavre Belgium

Name and address of the manufacturer responsible for batch release

GlaxoSmithKline Biologicals S.A. 89, rue de l'Institut

BE-1330 Rixensart Belgium

B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

Official batch release

In accordance with Article 114 of Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed